Key points are not available for this paper at this time.
@CPT anticancer platform, with its boosted •OH-producing capability and ROS-cleavable drug release, has been validated utilizing in vitro and animal studies, suggesting its capacity as a viable strategy for clinical trials.
Dirersa et al. (Tue,) studied this question.